Genmab — Maj 2019
-
Kan vi konkludere at der er en skuffelse i EnaV, men alt andet ser rigtig godt ud...., specielt dara sc, Janssen duobodies samt at isa iv ikke er bedre end dara iv
-
i am not sure you can conclude that yet, it is 'only' a safety trial so far, and it seems safety is manageable; they see sufficient reason to continue for now as they see "encouraging preliminary anti-tumor activity". We'll have to find out what that is...
-
to @GeorgeBest
-
Tak for forklaringer til, Solsen, Sukkeralf og EL...
-
Har man for mange Genmab aktier når ens humør påvirkes af aktiekursen ?
-
Jeg har ofte de samme tanker Tandfeen.
-
Genmab udgør også 99,4 % af mine aktier
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind